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Surface antigens on hematopoietic stem
cells (HSCs) enable prospective isolation
and characterization. Here, we compare
the cell-surface phenotype of hematopoi-
etic repopulating cells from murine yolk
sac, aorta-gonad-mesonephros, placenta,
fetal liver, and bone marrow with that of
HSCs derived from the in vitro differentia-
tion of murine embryonic stem cells (ESC-
HSCs). Whereas c-Kit marks all HSC popu-
lations, CD41, CD45, CD34, and CD150
were developmentally regulated: the earli-
est embryonic HSCs express CD41 and
CD34 and lack CD45 and CD150, whereas
more mature HSCs lack CD41 and CD34
and express CD45 and CD150. ESC-HSCs
express CD41 and CD150, lack CD34, and
are heterogeneous for CD45. Finally, al-
though CD48 was absent from all in vivo
HSCs examined, ESC-HSCs were hetero-
geneous for the expression of this mol-
ecule. This unique phenotype signifies a
developmentally immature population of
cells with features of both primitive and
mature HSC. The prospective fraction-
ation of ESC-HSCs will facilitate studies
of HSC maturation essential for normal
functional engraftment in irradiated
adults. (Blood. 2009;114:268-278)
Introduction
Defining the repertoire of cell-surface molecules that enables
hematopoietic stem cell (HSC) purification has been key to their
detailed functional characterization. Phenotypic changes of HSCs
can be correlated with changes in their cell cycle status, activa-
tion, and differentiation.1 As active sites of hematopoiesis transi-
tion during development from the yolk sac (YS) to the
aorta-gonads-mesonephros (AGM), to the placenta, to the fetal
liver (FL) and, finally, to the whole bone marrow (WBM),2 the
cell-surface phenotype of emerging HSCs also changes. The
earliest specific cell-surface marker of the hematopoietic lineage in
vivo, CD41, is expressed by HSC and hematopoietic progenitors in
the E9 YS and E10.5-E11.5 AGM but is absent from E14.5 FL and
WBM HSC.3-5 The pan-hematopoietic cell surface molecule,
CD45, does not appear on HSCs until the late AGM and FL stages
of development.6 In addition, in mice, CD34 is expressed by HSC
throughout development beginning at the E9 YS stage but disap-
pears from the most quiescent and primitive long-term WBM HSC
several weeks after birth.3,7 Thus, the cell-surface phenotype of
HSCs reflects their developmental maturity and origin.
HSCs are most rigorously defined by their ability to mediate the
long-term reconstitution of the major peripheral blood (PB)
compartments of primary and secondary recipients. Since the
isolation of embryonic stem cells (ESCs) from murine blastocysts,
researchers have attempted the derivation of transplantable HSCs.8-13
Our laboratory has reported the generation of engraftable HSCs
from ESCs via ectopic expression of HoxB4 in embryoid body
(EB)–derived cells followed by expansion on OP9 stroma.14 Before
this, transplantation of undifferentiated ESC, unpurified EB-
derived cells, or EB-derived cells transduced with oncogenes failed
to result in significant hematopoietic repopulation.8-10 Although
ESC-derived PgP-1/CD44Lin cells were reported capable of
long-term primary and secondary hematopoietic reconstitution, this
finding was never replicated.11 Most recently, c-KitCD45 EB-
derived cells have been found to manifest long-term hematopoietic
reconstitution in allogenic recipients and ameliorate the develop-
ment of diabetes in nonobese diabetic mice.12,13 However, long-
term reconstitution of secondary recipients via this system has not
yet been demonstrated.
We have refined our HoxB4-based protocol and established a
robust and reproducible system in which ESC-HSCs are engi-
neered from murine ESCs.15 EB-derived cells subjected to a pulse
of ectopic Cdx4 expression during EB differentiation are infected
with retroviral HoxB4 and then expanded on OP9 stroma. We call
the resulting heterogeneous population EPOCH cells (EB-derived,
Passed on OP9s and treated with ectopic Cdx4 and HoxB4). These
cells can rescue recipient animals from lethal irradiation, reconsti-
tute the entire hematopoietic compartment of primary and second-
ary recipients long term, and generate functional lymphocytes in
vivo.16-19 Retroviral marking demonstrates the presence of multilin-
eage, self-renewing hematopoietic repopulating cells within the
EPOCH cell population.15 However, because millions of EPOCH
cells are necessary to rescue mice from lethal irradiation, ESC-
HSCs are either exceptionally rare within this pool of cells or are
compromised in their capacity to engraft irradiated adult marrow.
Thus, a thorough characterization of the cell-surface phenotype of
the ESC-HSC, as has been done with in vivo HSC compartments, is
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crucial to their further study and characterization relative to the
various stages of HSC development in the embryo and in bone
marrow.
The authors of recent work20-23 have discovered that specific
hematopoietic lineages derived from human ESCs bear the hall-
marks of developmental immaturity: the attempted large-scale
production of erythrocytes chiefly generates nucleated cells lacking
adult globin gene expression. In addition, human ESC-derived
lymphoid progenitor populations are CD45low, indicative of devel-
opmental immaturity, and fail to generate B and T cells after in
vitro coculture with OP9- stromal cells or fetal thymus, apparently
attributable to a block in B- and T-cell development that biases
toward natural killer–cell differentiation.24-26 CD34 cells isolated
from 3- to 4-week-old human YS have demonstrated a similar
differentiation bias.27 Thus, ESCs appear predisposed toward the
production of developmentally immature hematopoietic popula-
tions. No data currently exist in mice or humans on the developmen-
tal status of ESC-HSCs. Because understanding the ontogeny of
HSC development in the murine embryo will facilitate the directed
differentiation of HSCs from ESCs, we have chosen to more
thoroughly characterize the cell-surface phenotype of murine
embryonic HSC populations. These experiments will also allow us
to more stringently compare ESC-HSCs to all in vivo HSC
compartments and place them within the hierarchy of HSC
development.
Methods
Cell culture and EPOCH cell generation
iCdx4 murine ESC and OP9 stromal cells (ATCC) were maintained as
previously described.28 EPOCH cell generation has been recently described
in detail.29 In brief, iCdx4 ESCs were differentiated in the presence of
ascorbic acid, mono-thioglycerol, and holo-transferrin for 48 hours as
hanging drops and then for an additional 4 days while shaking at 50 rpm.
Cdx4 gene expression was induced via doxycycline from day 3 to day 6 of
differentiation. At day 6, dissociated EBs were infected with MSCV-HoxB4-
internal ribosome entry site green fluorescent protein (IRES-GFP; multiplic-
ity of infection 5-10) in 6-well plates preplated with OP9 stromal cells.
After infection, cells were resuspended in Iscove modified Dulbecco
medium (IMDM) supplemented with 10% fetal calf serum, 2 mmol/L
penicillin/streptomycin/glutamine, 100 ng/mL human Flt3L, 100 ng/mL
human stem cell factor, 40 ng/mL murine vascular endothelial growth
factor, and 40 ng/mL human thrombopoietin, and then returned to their
original OP9 preplated 6-well plates for 7 days. At day 7 of OP9 coculture,
each plate was passaged into a 75-cm2 tissue culture flask with fresh IMDM
supplemented with serum and cytokines and cultured for an additional 3 to
5 days. All cytokines were obtained from Peprotech.
Embryo dissections and cell preparations
CD45.2 C57BL/6 mice were used for timed matings. Approval was
obtained from the institutional review board of Children’s Hospital Boston
for these studies. Embryonic day 0.5 (E0.5) equaled noon on the day of
vaginal plug. Embryos were collected at E9 (15-20 somite pairs), E11.5,
E12.5, and E14.5 for YS, AGM, placenta, and FL dissection, respectively.
YS, AGM, and placenta were washed repeatedly with phosphate-buffered
saline to minimize maternal blood contamination. YS was dissociated by
incubation in 1 mg/mL collagenase/dispase (Sigma) in IMDM for 1 hour at
37°C with occasional trituration. AGM was dissociated by incubation in
IMDM supplemented with 0.125% dispase (Invitrogen) for 30 to 45 min-
utes at 37°C with occasional trituration because preliminary studies
revealed that this treatment best preserved the colony-forming unit (CFU)
potential of c-KitCD34AGM cells (see supplemental Figure 1, available
on the Blood website; see the Supplemental Materials link at the top of the
online article). Each individual placenta was drawn through an 18-gauge
needle and incubated in IMDM plus 1 mg/mL collagenase/dispase (Sigma)
for 1.5 hours at 37°C with occasional trituration. Placenta-derived cells
were then overlaid on Ficoll (StemCell Technologies) and spun at 365g for
20 minutes to remove excess debris. FLs were dispersed via mashing on a
70-micron filter.
Cell fractionation
All cells were fractionated by either magnetic beads or fluorescence-
activated cell sorting (FACS). For FACS, a triple-LASER instrument
(FACSAria; BD Biosciences) was used, and 7-aminoactinomycin D or 4,6-
diamidino-2-phenylindole (Sigma) was used to exclude dead cells. For
magnetic bead selection, antiphycoerythrin microbeads (Miltenyi Biotec)
and LS columns (Miltenyi Biotec) were used according to the manufac-
turer’s instructions. The following antibodies were used for fractionation:
CD41 (MWReg-30), CD48 (HM48-1, Biolegend), CD48 (OX78, Abcam),
CD150 (TC15-12F12.2, Biolegend), CD34 (RAM34), c-Kit (2B8), and
CD45 (30-F11). Unless otherwise indicated, all antibodies were obtained
from BD Biosciences.
Transplants
For EPOCH cell transplants, C57BL/6 Rag-2/c/ mice weighing less
than 22 g were given 2 doses of 4.6 Gy of irradiation, separated by
2.5 hours, and transplanted via the lateral tail vein. For embryonic cell
transplants, CD45.1 C57BL/6 mice were given 2 doses of 5.5 Gy of
irradiation, separated by 2.5 hours, and transplanted with 2.5 105 CD45.1/
CD45.2 WBM cells plus CD45.2 embryonic cells via retro-orbital
injection. PB of recipients was analyzed every 4 weeks by FACS for
engraftment using the following antibodies: CD45.1 (A20), CD45.2, (104)
CD3 (145-2C11), CD4 (GK1.5), CD8 (536.7), CD19 (1D3), B220 (RA3-
6B2), IgM (11/41), Gr-1 (RB6-8C5), and Mac-1 (M1/70).
Results
CD150 is developmentally regulated on the cell surface of
HSCs
Although HSCs have recently been prospectively isolated from FL
and WBM based on the signaling lymphocyte activation molecule
(SLAM) markers CD48 and CD150, the expression of these
molecules has not been evaluated during HSC ontogeny.30,31 Thus,
we dissected AGM from E11.5 embryos (Figure 1A) and analyzed
CD48 and CD150 expression by FACS. Few AGM cells expressed
CD150 (0.24%; Figure 1B), whereas a larger percentage of CD48
cells was apparent (2%; Figure 1B). Interestingly, the CD150
AGM cells appeared enriched for CD41high cells relative to the
CD48 AGM compartment (Figure 1B). To assess which compart-
ments possessed HSC activity, we transplanted AGM-derived cells
fractionated based on CD150 and CD48 expression along with
competitor WBM into lethally irradiated recipients, taking advan-
tage of allelic differences in CD45 such that all sources of
repopulation in recipient animals could be discerned (Figure 1C;
Table 1). Whereas 3 of 8 mice transplanted with CD150CD48
AGM cells showed long-term multilineage AGM-derived PB
reconstitution (Figure 1D; Table 1), no mice transplanted with
CD48 or CD150 cells ever displayed evidence of AGM engraft-
ment (Table 1), indicating that the double-negative fraction con-
tains AGM HSC activity. Importantly, CD150CD48 AGM cells
were also capable of reconstituting the hematopoietic compartment
of secondary recipients (see supplemental Figure 2). We further
fractionated the CD150CD48 AGM cells for CD41 expression
and found HSC activity in both the CD41 and CD41 compart-
ments (see supplemental Figure 3; Table 1). These data suggest that
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AGM HSCs lose CD41 expression at this stage of development.
AGM cells purified with an alternate anti-CD48 antibody clone,
OX78, still failed to chimerize recipient animals (Table 1). Thus,
unlike their WBM and FL counterparts, AGM HSCs are
CD150CD48.
We next evaluated E12.5 placental HSCs for CD150 and CD48
expression (Figure 2A). The placenta harbors a large pool of
c-KitCD34med HSCs that peak in frequency at E12.5.32 We found
c-KitCD34med placental cells heterogeneous with respect to CD48
expression (Figure 2B). The repopulating potential of placental
HSCs with respect to CD48 expression was assessed via fraction-
ation by FACS and transplantation into lethally irradiated mice
(Figure 1C; supplemental Figure 4A; Table 2). In 4 independent
experiments, none of 18 mice transplanted with CD48 cells ever
displayed placenta-derived engraftment (Table 2). In contrast, 9 of
10 mice transplanted with CD48 cells displayed long-term multi-
lineage engraftment (Figure 2C; Table 2). We also fractionated
placental cells by using the anti-CD48 antibody clone, OX78, and
again found engraftment only in mice transplanted with CD48
cells (Table 2). These data argue strongly that placental HSC at
E12.5 lack CD48. Interestingly, both the CD41 and CD41
compartment of CD48 placenta cells engrafted recipient mice,
suggesting that E12.5 placental HSCs, like AGM HSCs, were
heterogeneous with respect to CD41 expression (Figure 2D; see
supplemental Figure 4B; Table 2).
We next examined whether placental HSCs express CD150. In
2 independent experiments, none of 4 animals transplanted with
CD150 placenta cells engrafted (Figure 2E; supplemental Figure
4C; Table 2). In contrast, 8 of 8 recipients of CD150 placenta cells
were highly engrafted in the PB more than 14 weeks after
transplant (Figure 2F; Table 2). These data demonstrate that E12.5
placental HSCs, like AGM HSCs, do not express CD150.
We also examined E9 YS for the expression of CD150 and CD48.
CD41highc-KitCD34 cells present in the E9 YS can support the
lifelong reconstitution of the hematopoietic compartment when trans-
planted into the neonatal liver.3 YSs were dissected from E9 embryos
(15-20 somite pairs), dissociated into a single-cell suspension by
treatment with collagenase/dispase, and then analyzed by flow cytom-
etry for the coexpression of CD41, c-Kit, CD34, CD150, and CD48. In
multiple independent analyses, we failed to detect CD48 or CD150
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Figure 1. E11.5 AGM-derived repopulating cells do not express CD150 or CD48. (A) E11.5 embryos before (i) and after (ii) AGM dissection. The image was captured at
room temperature by the use of a Leica MZ16 scope and a Nikon COOLPIX camera. Total magnification400. Arrows denote the aorta. (B) Flow cytometry analysis of CD48,
CD150, and CD41 expression on AGM cells. (C) To assess the in vivo hematopoietic repopulating potential of cells isolated from E11.5 AGM, E12.5 placenta, E14.5 FL, and
WBM, donor cells from each tissue were isolated from CD45.2 C57BL/6 mice, fractionated via FACS, and then transplanted into irradiated CD45.1 C57BL/6 mice along with
2.5  105 competitor WBM cells isolated from CD45.1/CD45.2 C57BL/6 mice. Recipient PB mice were then analyzed every 4 weeks for the presence of CD45.2 (ie,
donor-derived) cells. (D) A representative mouse 7 months after transplant with CD150CD48 E11.5 AGM-derived (CD45.2) B cells (IgM/CD19), T cells (CD3 and/or
CD4/CD8), and myeloid cells (Gr-1 and/or Mac-1).
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expression on either CD41 c-KitCD34 or total YS cells (Figure 3).
Thus, it appears likely that definitive HSCs present in the E9 YS lack
CD150 and CD48 expression.
Importantly, to verify that our failure to observe repopulating
activity in the CD150 compartment of AGM and placenta was not
caused by a technical inability to fractionate CD150 HSC, we
purified CD150 cells from FL and WBM and documented robust
reconstitution in recipient mice (see supplemental Figure 5).
In summary, our data demonstrate that CD150 is developmen-
tally regulated on the surface of HSCs: it is absent from repopulat-
ing cells in the E9 YS, E11.5 AGM, and E12.5 placenta but present
in the E14.5 FL and WBM. In contrast, CD48 is never expressed on
fetal or adult HSCs.
ESC-HSCs are CD41highCD34 but heterogeneous with respect
to CD45 expression
We next turned our attention to the characterization of the
cell-surface phenotype of murine ESC-HSCs derived by our
EPOCH protocol. To generate EPOCH cells, iCdx4 ESC were
exposed to doxycycline from day 3 to day 6 of EB differentiation,
infected with MSCV-HoxB4-IRES-GFP, and then expanded on
OP9 stroma in the presence of hematopoietic cytokines stem cell
factor, human Flt3 ligand, vascular endothelial growth factor, and
thyroid thrombopoietin for 10 days (Figure 4A). On average,
100 000 EB-derived cells plated on OP9 stroma at day 0 generated
68 ( 19%) hematopoietic colonies at day 7 of expansion and
ultimately resulted in 6.9  106  2.3  106 EPOCH cells by day
10 (see supplemental Figure 6A). These data suggest that OP9
colony-initiating cells are rare within the EB because only approxi-
mately 1 in 1500 EB-derived cells responds to HoxB4 infection by
robust expansion on OP9 stroma. We determined experimentally
that a minimum of 2-5  106 EPOCH cells are required to rescue
Rag-2/c/ mice from lethal irradiation (see supplemental
Figure 6B), indicating that the frequency of ESC-HSC within this
population is extremely rare.
Although EPOCH cells are highly enriched for CFUs relative to
WBM (see supplemental Figure 6C), we found that EPOCH cells
are not nearly as robust as WBM at rescuing mice from irradiation.
Although 2.5  105 WBM cells could rescue mice from up to
10.5 Gy of irradiation, 2  106 EPOCH cells could only rescue the
Table 1. E11.5 AGM-derived long-term repopulating cells are CD150CD48
AGM cell population % of population
Experimental
enrichment*
No. of embryo
equivalents transplanted
No. of AGM
cells transplanted, 104
No. reconstituted/no.
transplanted
% of long-term
reconstitution †‡
CD150CD48§ 0.03 nd 1 0.08 0/1
CD150CD48¶ 0.9-1.6 50-109 1.5-2 0.4-0.8 0/14
CD150CD48 0.1-0.8 38-115 1-2 0.05-0.5 0/3
CD150CD48¶ 97-98 1 1-2 26-41 3/8 0.8-26
CD150CD48CD41 95-96 1 1.5-2 39-42 2/6 21-63
CD150CD48CD41** 0.7-0.6 120-140 1-3.3 0.16-0.32 4/4 1.7-51
CD150CD48CD41§ 0.34 272 1.1 0.040 0/2
CD150CD48CD41§ 0.1 650 5.6 0.2 0/6
CD48 (OX78)§ 1.6 60 2 1 0/1
CD48 (OX78)§ 97 1 2 63 3/3 0.8-43††
*Experimental enrichment is calculated by dividing the frequency of the population after sort by the frequency of the population before sort.
†Reconstitution is defined as the presence of AGM-derived cells in both the myeloid and lymphoid compartments of the peripheral blood of mice undergoing
transplantation.
‡Reconstitution presented is based on the frequency of AGM-derived cells in the peripheral blood of mice undergoing transplantation at 17-24 weeks after transplantation.
§Data from 1 experiment.
¶Pooling of data from 4 independent experiments.
Pooling of data from 2 independent experiments.
** Pooling of data from 3 independent experiments.
††Eight weeks after transplantation.
Figure 2. E12.5 Placenta-derived repopulating cells do
not express CD150 or CD48. (A) E12.5 embryo after dissec-
tion of placenta. P indicates placenta; YS, yolk sac; and
E, embryo. The image was captured at room temperature by
the use of a Leica MZ16 scope and a Nikon COOLPIX
camera. Total approximate magnification12. (B) Flow cytom-
etry analysis of E12.5 placenta for CD34, c-Kit, and CD48
expression. Because the placenta contains a large population
of autofluorescent cells that make resolution of the
c-KitCD34med compartment difficult, we also dissociated
E12.5 FL and used it as a guide to gate c-KitCD34med
placenta cells (H. Mikkola, personal written communication,
October 2009). (C) A representative mouse 19 weeks after
transplantation with CD34medc-KitCD48 E12.5 placenta-
derived (CD45.2) B cells (IgM/CD19), T cells (CD3 and/or
CD4/CD8), and myeloid cells (Gr-1 and/or Mac-1).
(D) Flow cytometry analysis of CD48 and CD41 expression on
E12.5 placenta cells. (E) Flow cytometry analysis of CD150
expression on E12.5 placenta cells. (F) A representative
mouse 19 weeks after transplantation with CD150 E12.5
placenta-derived (CD45.2) B cells (IgM/CD19), T cells
(CD3 and/or CD4/CD8), and myeloid cells (Gr-1 and/or
Mac-1).
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majority of mice up to 9.25 Gy of irradiation (see supplemental
Figure 6D). Given that these doses of EPOCH cells or WBM have
similar numbers of CFU-S12 (see supplemental Figure 6E), these
data suggest inherent functional differences in the nature of the
hematopoietic progenitors in EPOCH cells versus WBM. Indeed,
preliminary work revealed that even an excess of EPOCH cells
mediate only transient hematopoietic engraftment when trans-
planted along with WBM competitor (data not shown). Thus, all
transplants of EPOCH described in this article are performed in the
absence of competitor WBM. Despite these functional differences,
EPOCH cells transplanted in the absence of competitor, under our
optimal conditions, routinely yield long-term, multilineage engraft-
ment of recipient mice (see supplemental Figure 6E).
The significant differences in the reconstituting ability of
ESC-derived EPOCH cells compared with WBM-derived HSC
prompted us to hypothesize that ESC-HSCs might resemble an
embryonic HSC compartment rather than adult bone marrow
HSCs. EPOCH cells are heterogeneous with respect to cell-surface
phenotype (Figure 4B). In a representative experiment, 80% and
39% of EPOCH cells expressed CD41 and CD45, respectively
(Figure 5A). EPOCH cells were fractionated on the basis of the
expression of these 2 molecules by magnetic bead selection to high
purity and transplanted into irradiated Rag-2/c/ recipients at
the indicated cell doses (see supplemental Figure 7A; Table 3).
Strikingly, in 2 independent experiments, all recipients of CD41
EPOCH cells perished by 20 days after transplant, whereas all
CD41 recipients were rescued for more than 90 days after
transplant (Figure 5B), 4 of whom displayed multilineage engraft-
ment for more than 26 weeks after transplant (Table 3; Figure 5C).
Surprisingly, 5 of 6 and 6 of 6 recipients of CD45 and CD45
EPOCH cells, respectively, also were rescued from lethal irradiation for
at least 90 days after transplant (Table 3; Figure 5B). Survivors from
each cohort also displayed multilineage engraftment for more than
26 weeks after transplant (Table 3; Figure 5C). In agreement with our in
vivo engraftment studies, CD41 EPOCH cells yielded far fewer CFUs
than CD41 EPOCH cells, whereas both CD45 and CD45 EPOCH
Table 2. E12.5 Placenta-derived long-term repopulating cells are CD150CD48
Placenta cell
population % of population
Experimental
Enrichment*
Number of embryo
equivalents
transplanted
Number of placenta cells
transplanted, 103
Number of
reconstituted/transplanted
% reconstitution
long-term†‡
c-KitCD48§ 12 8 0.5 31.5 1/1 86
c-KitCD48§ 8 12 0.5 22.3 0/5
c-KitCD34medCD48¶ 1.5-9 11-69 0.2-0.75 3.2-46.5 7/8 0.75-90
c-KitCD34medCD48¶ 1.7-4.6 21-54 0.2-1 4.6-14 0/18
CD48§ 72 1.4 0.5 115 1/1 93
CD48§ 24 4 0.75 36.8 0/2
CD41CD48§ 58 1.7 3 150 3/3 73-91
CD41CD48§ 6.7 11.5 7.5 45 2/3 70-83
CD41CD48§ 18 5.4 2.75 47 0/4
CD41CD48§ 1.5 66 4 4.3 0/4
CD48 (OX78)§ 92 1 1 168 3/3 71-78**
CD48 (OX78)§ 3.2 31 1 25 0/2
CD150†† 88-92 1-1.2 0.5-0.9 4.4-10 8/8 40-86
CD150†† 7-7.6 11.5-13.9 0.5-0.7 150-870 0/4
*Experimental enrichment is calculated by dividing the frequency of the population after sort by the frequency of the population before sort.
†Reconstitution is defined as the presence of placenta-derived cells in both the myeloid and lymphoid compartments of the PB of transplanted mice.
‡Reconstitution presented is based on the frequency of placenta-derived cells in the peripheral blood of mice undergoing transplantation at 19-27 weeks after
transplantation.
§Data of 1 experiment.
¶Pooling of data from 4 independent experiments.
Because of contamination of CD41 cells in the CD41CD48 population, cannot rule out possibility that CD41CD48 engraftment is CD41 derived.
**Eight weeks after transplant.
††Pooling of data from 2 independent experiments.
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Figure 3. CD150 and CD48 expressing cells are not
detectable in E9 YS. Representative analysis of E9
YS-derived cells analyzed by flow cytometry for the cell
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cells contained significant CFU activity (see supplemental Figure 8A).
These data reveal that although ESC-HSCs uniformly express CD41,
they are heterogeneous with respect to CD45 expression.
Coexpression analysis of CD45 and CD41 on EPOCH cells
reveals, as our transplantation data would predict, that the CD41
EPOCH cell compartment is heterogeneous with respect to CD45
(Figure 5D). Interestingly, c-Kit expression segregates with the
CD41 cells expressing the highest levels of CD41 (Figure 4C).
Previous studies3 have shown that the most definitive hematopoi-
etic progenitors during development express high levels of CD41,
whereas primitive hematopoietic progenitors are CD41low. To
determine whether ESC-HSCs could be restricted to the CD41high
EPOCH cell compartment, we performed 2 independent experi-
ments in which CD45CD41low, CD45CD41high, CD45CD41low,
and CD45CD41high EPOCH cells were transplanted into Rag-2/
c/ recipients (see supplemental Figure 7B). All 12 recipients
of CD41low EPOCH cells succumbed to lethal irradiation by
25 days after transplant, whereas 8 of 12 recipients of CD41high
cells were rescued (Figure 5E; Table 3).
Although recipients of both CD45CD41high and CD45CD41high
maintained engraftment out to at least 22 weeks after transplant, the
recipients of CD45CD41high cells appeared to maintain a greater
level of long-term engraftment (Figure 5F). In addition, in one
experiment, CD45CD41high EPOCH cells were enriched for
CFU-GEMM activity relative to CD45CD41high cells (see supple-
mental Figure 8B). Interestingly, EPOCH cells expressing the
greatest levels of c-Kit either lack CD45 or express only moderate
levels of this molecule (Figure 4C). C-Kit is expressed by HSC
throughout development, whereas CD45 expression levels have
been linked to developmental immaturity.33,34 In summary, these
data reveal that ESC-HSCs express high levels of CD41 and
although heterogeneous with respect to CD45 expression, the
most potent long-term ESC-HSCs express only moderate levels
of this molecule.
To further refine the cell-surface phenotype of ESC-HSCs, we
examined the coexpression of CD41 and CD34 on EPOCH cells.
CD41 EPOCH cells are heterogeneous for CD34 expression
(Figure 5G). EPOCH cells were fractionated by FACS based on the
expression of CD34 alone or both CD41 and CD34 and trans-
planted into Rag-2/c/ recipient mice (see supplemental
Figure 7C). All 10 recipients of CD34 EPOCH cells perished by
20 days after transplantation, whereas 8 of 9 recipients of CD34
EPOCH cells were rescued for at least 90 days after transplant
(Figure 5H; Table 3). All recipients of CD41CD34 EPOCH cells
maintained high-level EPOCH cell-derived PB chimerism at
18 weeks after transplant (Figure 5I). Thus, ESC-HSCs do not
express CD34. The phenotypic analyses presented thus far reveal
that murine ESC-HSCs are restricted to the CD41highCD34
fraction of EPOCH cells but that this cell compartment is heteroge-
neous with respect to CD45 expression, with the most potent
ESC-HSCs expressing intermediate levels of CD45.
ESC-HSCs are CD150 but heterogeneous with respect to
CD48 cell-surface expression
High CD41 and moderate CD45 expression reveals that ESC-HSCs
phenotypically resemble developmentally immature HSCs. Given
our data that CD150, like CD41 and CD45, is developmentally
regulated on HSCs, we next evaluated the expression of the SLAM
family members, CD150 and CD48, on the surface of EPOCH
cell-derived ESC-HSCs.
EPOCH cells were fractionated by magnetic selection into
CD48 and CD48 subsets and transplanted into Rag-2/c/
recipient mice (Figure 6A). In 2 independent experiments, 2 of
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3 recipients of CD48 cells and 5 of 6 recipients of CD48 cells
were rescued from lethal irradiation 4 weeks after transplant
(Figure 6B; Table 3). Surprisingly, mice from both cohorts of
animals maintained high EPOCH cell-derived PB chimerism for at
least 26 weeks after transplant (Figure 6C; Table 3). These data
suggest that ESC-HSCs can be found in both the CD48 and
CD48 subsets of EPOCH cells. We next examined CD41high
EPOCH cells for the coexpression of CD150 and CD48. CD41high
EPOCH cells nearly uniformly express CD150 (Figure 6D). Three
distinct populations within this compartment can be clearly
resolved on the basis of CD48 expression: CD48/low, CD48med,
and CD48high. These 3 populations were purified by FACS and
transplanted into Rag-2/c/ recipients (Figure 6D). Each
cohort was capable of rescuing mice from lethal irradiation and
maintaining PB chimerism 22 to 29 weeks after transplant
(Figure 6E-F; Table 3).
In summary, murine ESC-HSCs possess phenotypic hallmarks
of developmental immaturity such as high CD41 expression and
moderate CD45 expression, but like more mature FL and bone
marrow HSCs, ESC-HSCs also express CD150 (Figure 7). Thus,
ESC-HSCs present a unique cell-surface phenotype, distinct
from any in vivo HSC population analyzed, that reflects a
developmentally immature admixture of cells transitioning
between embryonic and adult phenotypes. Furthermore, in sharp
contrast to all in vivo HSC compartments, which lack CD48
expression, ESC-HSCs are heterogeneous with respect to CD48,
with most of these cells expressing either moderate or high
levels of this molecule (Figure 7).
Discussion
Here, we demonstrate that ESC-HSCs are CD41bright, c-Kit,
CD34, and heterogeneous for CD45. These data suggest that
ESC-HSCs show greater similarity to early developmental HSC
populations than adult WBM-HSCs. We have examined embry-
onic HSCs and ESC-HSCs for the cell-surface expression of
CD48 and CD150, 2 members of the SLAM family of cell-
surface molecules that have proven useful in high-purity
prospective isolation of FL and WBM hematopoietic progeni-
tors.30,31 We demonstrate that CD150 is developmentally regu-
lated on the cell surface of embryonic HSC: it is absent on E9
YS, E11.5 AGM, and E12.5 placenta HSCs but present on E14.5
FL and WBM HSC. ESC-HSC also express CD150 but are
heterogeneous for CD48 expression.
Figure 5. ESC-HSC are CD41highCD34 and heterogeneous with respect to CD45 cell-surface expression. (A) CD41 and CD45 expression on EPOCH cells is shown.
(B) Kaplan-Meier survival analyses and (C) EPOCH cell-derived PB reconstitution of Rag-2/c/ mice transplanted with EPOCH cells fractionated for CD41 or CD45
expression. EPOCH cell-derived PB is GFP. Two independent experiments are presented. (D) CD45 and CD41 coexpression on EPOCH cells are shown. (E) Shown are
Kaplan-Meier survival analyses and (F) EPOCH cell-derived PB reconstitution of Rag-2/c/ mice undergoing transplantation with EPOCH cells fractionated for both CD41
and CD45 expression. Two independent experiments are presented. Error bars denote standard deviation. (G) CD41 and CD34 expression on EPOCH cells. (H) Kaplan-Meier
survival analyses and (I) EPOCH cell-derived PB reconstitution of Rag-2/c/ mice undergoing transplantation with EPOCH cells fractionated for CD34 expression are
shown. Data in panel H summarize 4 experiments. Data in (I) summarize 7 CD34 recipients.
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Before the current study, little was known regarding the basic
biology of ESC-HSCs. Given that these cells are engineered
from pluripotent cells predisposed to generate developmentally
immature hematopoietic populations,20-26 a careful examination
of the cell-surface phenotype of ESC-HSCs side by side with
embryonic HSC compartments is crucial. By identifying cell
surface markers that both allow for their prospective purification
and their placement during HSC development, we can develop
new strategies that allow us to direct these cells into adult-like
WBM-HSCs.
HSCs are best defined functionally. Our EPOCH protocol
allows for the robust and reproducible generation of cells from
murine ESCs that meet a strict functional definition of HSCs:
they rescue mice from lethal irradiation and maintain long-term
chimerism.15 Most importantly, retroviral marking studies have
demonstrated clonal multilineage PB repopulation of primary
and secondary mice by ESC-HSCs engineered in this manner.15
The ability of HoxB4 overexpression to induce the development
of hematopoietic progenitors in differentiating human and
mouse ESC is being actively explored by several groups.
Cumulatively, the data suggest that the level of HoxB4 expres-
sion significantly affects the degree of hematopoietic specifica-
tion, with moderate levels of HoxB4 expression optimal for
hematopoietic induction.35-38 Significantly, hematopoietic repopu-
lating cells derived from murine ESC via HoxB4 overexpression
can induce tolerance in recipient mice, allowing for the accep-
tance of cardiac allografts.16 This system also allows for the
derivation of repopulating cells from induced pluripotent cells,
revealing that HoxB4 overexpression can effect the derivation of
ESC-HSCs from multiple pluripotent cell types.18 Given that
this protocol is being broadly applied to both mouse and human
pluripotent cell populations, better characterization of the
resulting hematopoietic repopulating cells is imperative.
Our study represents a thorough characterization of the
phenotype of EPOCH cell-derived ESC-HSCs. They express
high levels of CD41, are c-Kit and CD150, and lack CD34
expression (summarized in Figure 7). Surprisingly, EPOCH
cells harbor a phenotypic mixture of ESC-HSCs as revealed by
the heterogeneous expression of CD45 and CD48, although the
most potent ESC-HSCs appear to express moderate levels of
CD45. CD41 is a molecule that is expressed by HSC and
progenitors in the YS, AGM, and placenta but is lost by the FL
stage of development.3-5 In contrast, CD45 is not acquired by
HSCs and progenitors until the late AGM stage of develop-
ment.6 Although CD34 is expressed by most HSCs throughout
development, CD34-repopulating cells have been detected in
the AGM.7,39 Thus, ESC-HSCs phenotypically resemble HSCs
that emerge early in development, suggesting that they them-
selves are developmentally immature. The apparent developmen-
tal immaturity of ESC-HSCs is consistent with the embryonic
origin of the cells and perhaps reflects incomplete maturation or
differentiation of the cultured cells. We are currently comparing
the global gene expression profiles of purified ESC-HSCs with
in vivo HSCs purified from throughout ontogeny in an attempt
to more accurately define the developmental state of these
in vitro derived cells. These studies will illuminate to which
in vivo HSC compartment ESC-HSCs engineered in this context
are most similar. Although, given their unique origin, it is very
possible that ESC-HSCs will have no direct in vivo equivalent.
However, by elucidating their cell-surface phenotype, we have
provided a strategy by which these cells can now be prospec-
tively purified and their biology studied in greater detail.
We have also demonstrated that CD150 is a developmentally
regulated molecule on the surface of HSCs. Although WBM and
FL HSC express CD150, a fact that we verified ourselves
experimentally in this study, HSCs from the YS, AGM, and
Table 3. Summary of ESC-HSC phenotype transplants
EPOCH cell population
No. of unfractionated
equivalents transplanted,
 106*
No. of cells
transplanted, 106
No. of mice rescued at
4 wks after transplant/
no. transplanted
Peripheral blood
engraftment long-term†
No. of animals displaying
multilineage engraftment‡
CD41§ 3-5 1.9-4.4 6/6 15.5%-85% 4
CD41§ 3-5 0.6-1.1 0/6
CD45§ 3-5 1.4-2 5/6 1%-41% 2
CD45§ 3-5 1.7-3 6/6 3.6%-64% 2
CD45CD41low§ 2-3 0.14-0.3 0/6
CD45CD41low§ 2-3 0.12-0.11 0/6
CD45CD41high§ 2-3 0.13-0.3 5/6 9.7%-63% 1
CD45CD41high§ 2-3 0.4-0.5 3/6 83%-91% 1
CD34 2.5 0.125 0/3 nd nd
CD34 2.5 1.4 1/2 nd nd
CD41CD34§ 1.5-2 0.023-0.3 0/6
CD41CD34§ 1.5-2.5 0.3-0.9 4/4 4.3%-91% 3
CD48§ 5 1.75-1.8 2/3 8.4%-65% 1
CD48§ 5 2.8-3.1 5/6 1.5%-90% 3
CD41highCD150CD48-¶ 2-5 0.016-0.4 2/7 7.2%
CD41highCD150CD48med¶ 2-5 0.35-0.75 4/11 2.4% 1
CD41highCD150CD48¶ 2-5 0.5-1 6/9 0.2%-14.4% 3
nd indicates not determined.
*Unfractionated equivalent numbers are calculated based on the frequency of each phenotypic subpopulation within the total EPOCH population. For example, 1  105
cells of a subset of cells representing 10% of the total population would be equivalent to 1 000 000 unfractionated EPOCH cells.
†Peripheral blood engraftment based on the frequency of green fluorescent protein-positive cells in the peripheral blood of surviving mice undergoing transplantation at
 18 weeks after transplantation.
‡ Multilineage engraftment is defined by the presence of cells in the PB of mice undergoing transplantation coexpressing green fluorescent protein and Mac-1 and/or Gr-1
(myeloid engraftment) and cells expressing CD19 and/or IgM (B cells) or CD3 and CD4/CD8 (T cells) 22 weeks after transplantation.
§Pooling of data from 2 independent experiments
¶Pooling of data from 4 independent experiments.
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placenta do not (summarized in Figure 7).30,31 Thus, CD150 is
acquired by HSC after the placenta stage of development. This
finding adds to the repertoire of cell-surface molecules whose
regulation can be studied to classify and characterize HSC at
distinct developmental stages. Interestingly, although CD150
appears absent from the most developmentally immature HSC,
it is expressed by ESC-HSCs. The expression of CD150 by this
developmentally immature compartment could be a conse-
quence of the extensive coculture of these cells with OP9 stroma
(ie, the result of in vitro culture within an adult bone marrow
microenvironment). Alternatively, the expression of CD150, in
conjunction with the fact that ESC-HSCs are phenotypically
heterogeneous with respect to CD45, suggests that EPOCH cells
may consist of a pool of ESC-HSCs transitioning from a
developmentally immature phenotype (CD45) to a developmen-
tally mature phenotype (CD45CD150). A CD45CD150
repopulating cell has never been identified in the murine
embryo, perhaps because the transition from CD45CD150 to
CD45CD150may occur quickly in vivo and be too transient to
capture via the methods used in the current study or may take place
at an anatomic site not yet carefully examined for heterogeneity of
CD45 expression (ie, the placenta). Finally, it is possible that the
in vitro derivation of ESC-HSCs by the use of ectopic HoxB4
expression might result in a phenotype that does not formally
correlate with an in vivo compartment.
Figure 6. ESC-HSC are CD150 and heterogeneous with respect to CD48 cell-surface expression. (A) CD48 and CD48 EPOCH cells were isolated by magnetic bead
selection and analyzed by flow cytometry before and after fractionation. (B) Kaplan-Meier survival analyses and (C) EPOCH cell-derived PB reconstitution of Rag-2/c/
mice transplanted with CD48 EPOCH cells fractions. EPOCH cell-derived PB is GFP. Data are pooled from 2 experiments. (D) CD48, CD48med, and CD48 CD41high
CD150 EPOCH cells were isolated via FACS. A representative before- and after-sort analysis is shown. (E) Kaplan-Meier survival analyses and (F) EPOCH cell-derived PB
reconstitution of Rag-2/c/ mice transplanted with CD41high EPOCH cells fractionated for CD150 and CD48 expression are shown. Data are pooled from 4 experiments.
Error bars denote standard deviation.
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Figure 7. Cell surface phenotype of embryonic and ESC-derived HSCs. Our data
further defines the cell-surface phenotype of both murine ESC-HSCs and in vivo
HSCs during ontogeny, especially with regard to the expression of the SLAM family of
cell surface molecules. Similarly to early developmental HSC populations in the YS
and AGM, ESC-HSCs express high levels of CD41. ESC-HSCs lack CD34 expres-
sion and are heterogeneous for both CD48 and CD45 cell-surface expression,
suggesting that they represent a pool of phenotypically distinct repopulating cells.
Surprisingly, we found that CD150 expression is developmentally regulated during
HSC ontogeny; it is absent from E11.5 AGM and E12.5 placental HSCs but present
on E14.5 FL and WBM HSC. CD48 was absent from HSCs throughout ontogeny.
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Our data also revealed that CD48 is absent from steady-state
HSCs throughout development. We were never able to detect
CD48 expression on repopulating cells in the E9 YS, E11.5
AGM, E12.5 placenta, or E14.5 FL, and CD48 is reportedly
absent from WBM-HSCs. Thus, we were surprised by our
observation that the majority of ESC-HSCs express this mole-
cule. Recently, phenotypic HSC expressing CD48 have been
detected in WBM after treatment with 5-FU or after in vitro
culture.40,41 Multiple studies have shown that a greater propor-
tional of these cells are in the S/G2/M phase of the cell cycle,
although one study did not observe repopulating potential when
these cells were transplanted.40,41 Although the expression of
CD48 by ESC-HSCs suggests an actively cycling HSC popula-
tion, our own preliminary analyses find no difference in the cell
cycle status of CD48 and CD48 EPOCH cells. The majority
( 95%) of CD41brightCD150CD48 and CD41brightCD150
CD48 populations are in the G0/G1 phase of the cell cycle (data
not shown). These data correlate with our observation that ESC-
HSCs lack CD34 expression (Figure 5; Table 3). Thus, CD48 does
not appear to correlate strongly with repopulating potential in
ESC-HSC populations.
Our study further establishes that ESCs are predisposed to
generate developmentally immature hematopoietic populations in
vitro. Although both murine and human ESCs can generate
adult-type progenitors, as reported in some of the original work
characterizing spontaneous hematopoietic differentiation of EBs,42,43
the authors of multiple studies20-26 have found that ESCs forced to
generate large numbers of red blood cells and lymphocytes yield
cells resembling these populations’ immature counterparts. Further-
more, repopulating cells isolated from both human and mouse
ESCs are transplanted most efficiently when introduced intrafemo-
rally.12,38 These data suggest that ESC-derived cells are defective in
homing to marrow after transplantation, similarly to what has been
shown for pre-HSCs that emerge in the E9 YS.3 Inappropriate
homing likely contributes to the apparent paucity of functional
ESC-HSCs present within the EPOCH population. Preliminary
studies reveal that although CD41highCD34 EPOCH cells are
homogeneous for cell surface 	4
1 intergrin expression, only a
subset express CXCR4 (see supplemental Figure 9). Further work
will be required to determine the functional significance of these
observations.
Finally, it has recently been shown that cells with limited
repopulating potential can be engineered from human ESCs via
AGM-derived stromal cell coculture, suggesting that such cells are
primed to respond to a developmental microenvironment.44 This
work, in conjunction with our own, highlights the importance of
developing strategies to induce the maturation of ESC-derived
hematopoietic populations toward phenotypic and functional matu-
rity such that they behave as bona fide bone marrow–derived
HSCs. During the past several years, stromal cell lines isolated
from distinct developmental microenvironments have been identi-
fied that can support HSCs in culture.45,46 Both mouse and human
ESCs have been cultured with these lines, resulting in enhanced
hematopoietic differentiation and the derivation of cells with
limited repopulating potential from human ESCs.44,46 Recent work
has begun to define the intermediate populations that emerge both
during normal HSC development and during the in vitro differentia-
tion of ESC along the hematopoietic lineages. For example,
hematopoietic progenitors emerging in differentiating EBs transi-
tion through brachyury and Flk-1 intermediates as they progress
from mesoderm to the hemangioblastic lineage.47 A study by
Taoudi et al48 has demonstrated that most HSCs that emerge
between E11.5 and E12.5 in the developing embryo are likely
derived from a VE-cadherinCD45 precursor found in the
intra-aortic clusters of the AGM. If the in vitro correlates to these
key in vivo transitional populations were identified, then our
strategy for directing the fate of differentiating ESCs toward HSCs
could be refined by placing these populations in the appropriate
developmental microenvironment and perhaps allowing for their
complete maturation to WBM-like HSCs. Indeed, investigators
have already begun to define the key signals promoting HSC
maintenance emanating from these developmental stromal lines.49
In the meantime, the ESC-HSCs generated in our system remain a
valuable tool for further study by allowing us to better understand
the key pathways regulating both ESC differentiation and HSC
development.
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